AuPS Logo Programme
Contents
Previous Next PDF

Mixed antagonistic effects of the ginkgolides at recombinant human ρ1 GABAC receptors

S.H. Huang,1 T.M. Lewis,2 S.C.R. Lummis,3 A.J. Thompson,3 M. Chebib,4 G.A.R. Johnston1 and R.K. Duke,1 1Discipline of Pharmacology, School of Medical Sciences, The University of Sydney, NSW 2006, Australia, 2School of Medical Sciences, The University of New South Wales, NSW 2052, Australia, 3Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom and 4Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia.

Ginkgolides A, B and C are diterpene lactones found in the leaves of the Ginkgo biloba tree. They are known to be non-competitive antagonists at α1β2γ2L GABAA receptors (Huang et al., 2004) and glycine receptors (Hawthorne et al., 2006; Heads et al., 2008). These receptors are both anion-selective channels of the pentameric ligand-gated ion channel family. The subunits that make up these receptors share a similar topology, with a large extracellular N-terminus that forms the ligand binding site, four transmembrane domains (M1-M4) and a short extracellular C-terminus. The M2 domain from each subunit forms the channel pore. Evidence suggests that ginkgolides bind within the channel pore by interacting with M2 residues (Hawthorne et al., 2006; Heads et al., 2008).

The effects of ginkgolides A, B and C were examined on recombinant human ρ1 GABAC receptors expressed in Xenopus oocytes. Whole-cell currents were recorded using standard two-microelectrode voltage-clamp methods. Oocytes were clamped at –60 mV and continuously superfused with ND96 buffer. GABA concentration-response curves were compiled from a range of GABA concentrations (0.01 − 100 μM) applied alone or co-applied with a fixed concentration of ginkgolide (10 μM, 30 μM or 100 μM) in ND96 buffer. The GABA EC50 value was 1.02 ± 0.05 μM (n=15) and with increasing ginkgolide concentration there was an approximately parallel shift to the right of the curves and a decrease in the maximum response. Ginkgolide A (n=5) was the least potent of the three compounds, with a 1.9-fold, 2.3-fold and 2.5-fold increase in the EC50 value in the presence of 10, 30 and 100 μM respectively, with a maximum response of 86 ± 1% at 100 μM. Ginkgolide B (n=6) was the most potent, with 3.2-fold, 4.7-fold and 7.5-fold increases in the EC50 and a maximum response of 70 ± 2% at 100 μM. Ginkgolide C (n=4) was similar to ginkgolide B, with 3.8-fold, 6-fold and 5.3-fold increases in the EC50 and a maximum response of 73 ± 3% at 100 μM. Inhibition curves were compiled from a range of ginkgolide concentrations co-applied with 0.5 μM (∼EC15 GABA), 1.2 μM (∼EC50), 3 μM (∼EC80) or 10 μM (∼EC100) test concentrations of GABA in ND96 buffer. Each of the ginkgolides A, B and C exhibited increased IC50 values with increasing GABA concentrations. These results are indicative of a mixed-antagonism effect and in an attempt to explain these results a simple allosteric mechanism of inhibition was fitted to the data. With such an allosteric kinetic scheme, the rightward shift in the concentration response curves is accounted for by an increase in the GABA equilibrium dissociation constant (decrease in affinity) in the presence of ginkgolides, and a decrease in the equilibrium for the channel opening reaction (decrease in open probability) accounts for the decrease in maximum response. However, not all characteristics of the inhibition curves were adequately predicted by such a scheme. The difference in antagonism at ρ1 GABAC receptors compared to GABAA and glycine receptors may be due to subtle differences in the amino acid residues located at the bottom of the channel pore, where the ginkgolides are thought to bind.

Hawthorne, R., Cromer, B.A., Ng, H.-L., Parker, M.W. and Lynch, J.W. (2006) Journal of Neurochemistry 98, 395-407.

Heads, J.A., Hawthorne, R.L., Lynagh, T. and Lynch, J.W. (2008) Journal of Neurochemistry 105, 1418−1427.

Huang, S.H., Duke, R.K., Chebib, M., Sasaki, K., Wada, K. and Johnston, G.A.R. (2004) European Journal of Pharmacology 494, 131−138.